Twice-Yearly Lenacapavir for PrEP Reduces HIV Infections by 96%
Twice-yearly injections of the capsid inhibitor drug lenacapavir can prevent the vast majority of HIV infections, according to a Phase 3 clinical trial published Wednesday in the New England Journal of Medicine. HIV pre-exposure prophylaxis (PrEP) has emerged as a crucial tool for fighting the global HIV epidemic, but researchers say daily pill regimens [...]









